Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORTD-1 for Hospitalized COVID-19 Pneumonia
NCT04708236Phase 2Withdrawn
- Sponsor
- Oryn Therapeutics
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ORTD-1 in COVID-19 pneumonia, sponsored by Oryn Therapeutics. Planned start Apr 2021; status: withdrawn.
02
Drugs
ORTD-1
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04708236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708236.